Ery­tech col­lab­o­rates on rare dis­ease drug; En­terome cre­ates di­ag­nos­tics ven­ture with Nestlé

⟶ France’s Ery­tech has forged a col­lab­o­ra­tion with Queen’s Uni­ver­si­ty in Cana­da on their erymi­nase pro­gram specif­i­cal­ly for the treat­ment of arginase-1 de­fi­cien­cy, a rare and se­vere meta­bol­ic dis­or­der re­lat­ed to argi­nine me­tab­o­lism. “This is our sec­ond col­lab­o­ra­tion in the field of rare meta­bol­ic dis­eases that un­der­scores the scope of our plat­form and its ap­plic­a­bil­i­ty to high­ly spe­cial­ized and rare con­di­tions be­yond on­col­o­gy,” said CSO Alexan­der Scheer.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN